In utero exposure to ADHD drugs not linked to developmental disorders
The Brown University Psychopharmacology Update May 28, 2023 DOI: 10.1002/pu.31038 (opens in new tab) via Semantic Scholar
Summary
AI-generated from the abstractPeople who microdosed expected changes in 18 affective states, including anger, anxiety, calmness, cognitive functioning, craving, creativity, feeling connected, energy, focus, guilt, happiness, meditative state, motivation, openness, sadness, self-efficacy, stress, and well-being. At the final visit, they reported whether microdosing actually changed these states. Adverse events were recorded. Blinding was assessed on each dose day by asking participants to guess if they received LSD or placebo.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Intervention | LSD |
| Keywords | Psychology Medicine |
Abstract
expected the microdosing to change how they felt on measures of 18 affective states: angry, anxious, calm, cognitive functioning, craving, creative, connected, energy, focused, guilty, happy, meditative, motivated, open, sad, self-efficacy, stressed, and well. They were asked at the final visit to report whether microdosing actually did result in change in these states. Data on adverse events were collected. The investigators evaluated blinding on each dose day by asking participants to guess whether they had received LSD or placebo.